Page 113 - Read Online

Gawel et al. J Cancer Metastasis Treat 2022;8:26 https://dx.doi.org/10.20517/2394-4722.2022.13 Page 9 of 11

Financial support and sponsorship
This work was supported by Abbott Laboratories.

Conflicts of interest
All authors are employees of Abbott Laboratories.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. American Cancer Society. Lifetime risk of developing or dying from cancer. 2020; Available from:
https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html. [Last accessed on 29 June
2022].
2. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin 2019;69:363-85.
DOI PubMed
3. Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Ther Adv Med
Oncol 2018;10:1758835918794630. DOI PubMed PMC
4. Morgan TM. Liquid biopsy: Where did it come from, what is it, and where is it going? Investig Clin Urol 2019;60:139-41. DOI
PubMed PMC
5. Rossi G, Ignatiadis M. Promises and pitfalls of using liquid biopsy for precision medicine. Cancer Res 2019;79:2798-804. DOI
PubMed
6. Casanova-Salas I, Athie A, Boutros PC, et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical
decision-making in prostate cancer. Eur Urol 2021;79:762-71. DOI PubMed PMC
7. Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MHA, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight
against cancer. Oncotarget 2018;9:2912-22. DOI PubMed PMC
8. Li D, Lai W, Fan D, Fang Q. Protein biomarkers in breast cancer-derived extracellular vesicles for use in liquid biopsies. Am J Physiol
Cell Physiol 2021;321:C779-97. DOI PubMed
9. Werner S, Keller L, Pantel K. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. Mol Aspects Med
2020;72:100817. DOI PubMed
10. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7. DOI PubMed
11. Lennon AM, Goggins M. Diagnostic and therapeutic response markers, Pancreatic Cancer. New York, NY: Springer, 2010; pp. 675-
701.
12. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal
cancer. J Clin Oncol 2006;24:5313-27. DOI PubMed
13. Bhardwaj M, Gies A, Werner S, Schrotz-King P, Brenner H. Blood-based protein signatures for early detection of colorectal cancer: a
systematic review. Clin Transl Gastroenterol 2017;8:e128. DOI PubMed PMC
14. Yang D, Zhang X, Powell CA, et al. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker
panel in China: LCBP study. Cancer 2018;124:262-70. DOI PubMed
15. Hsu T, Liu T, Gould B, et al. Abstract PO-007: plasma-based detection of pancreatic cancer: A multiomics approach. Cancer Res
2021;81:PO-007. DOI
16. Cai Z, Zhang J, He Y, et al. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein
biomarkers for diagnosis and prognosis of hepatocellular carcinoma. ESMO Open 2021;6:100021. DOI PubMed PMC
17. Guo D, Sun J, Wang Y, et al. 956P A multi-analyte liquid biopsy assay integrating cfDNA methylation and protein biomarkers for
liver cancer diagnosis. Ann Oncol 2021;32:S828. DOI
18. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer
patients. Cancer Res 2001;61:4675-78. PubMed
19. Wroclawski ML, Serpa-Neto A, Fonseca FL, et al. Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of
prostate cancer patients. Tumour Biol 2013;34:2921-7. DOI PubMed
20. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science
2018;359:926-30. DOI PubMed PMC